Zalicus Granted Key Formulation Patent for Z160
Extends Z160 Patent Coverage through March 2032
CAMBRIDGE, Mass. -- April 02, 2013
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain,
today announced that it has been granted a patent by the U.S. Patent and
Trademark office (USPTO) covering novel formulations of its product candidate
Z160. United States patent number 8,409,560, entitled “Solid Dispersion
Formulations and Methods of Use Thereof,” provides broad coverage for a range
of novel Z160 pharmaceutical compositions and methods of using these
compositions in the treatment of pain.
“We are delighted to have been issued this important patent extending Z160’s
patent protection and exclusivity into 2032,” commented Mark H.N. Corrigan,
MD, President and CEO of Zalicus. “Solid dispersion technology is
well-characterized and has been utilized in a number of commercial and
late-stage development products. Building on this knowledge, Zalicus has
developed solid dispersion formulations of Z160 that have uniquely improved
its bioavailability and have facilitated its advancement into two ongoing
Phase 2a clinical trials in chronic neuropathic pain.”
Zalicus is currently advancing Z160, a first-in-class, oral, state-dependent,
selective N-type calcium channel (Cav 2.2) blocker, through Phase 2a clinical
development in chronic neuropathic pain. Z160 is designed to selectively
target neuronal pain signaling by modulating neurons that are undergoing
high-frequency firing. Z160 has demonstrated efficacy in multiple animal
models of neuropathic and inflammatory pain, suggesting that it has the
potential to treat a broad range of chronic pain conditions. Additionally,
clinical trials in over 200 subjects have established Z160 as a safe and well
tolerated drug candidate. N-type calcium channels have been recognized as key
targets in controlling pain because of their key role in transmitting pain
through the spinal nerves to the brain.
Zalicus Inc. (Nasdaq Global Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain such as Z160 and Z944 and has entered into multiple
revenue-generating collaborations with large pharmaceutical companies relating
to other products, product candidates and drug discovery technologies. Zalicus
applies its expertise in the discovery and development of selective ion
channel modulators and its combination high throughput screening capabilities
to discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn more
about Zalicus, please visit www.zalicus.com.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
product candidate Z160, its potential, its formulation and plans for its
clinical development. These forward-looking statements about future
expectations, plans, objectives and prospects of Zalicus and its product
candidates may be identified by words like "believe," "expect," "may," "will,"
"should," "seek," “plan,” “project” or “could” and similar expressions and
involve significant risks, uncertainties and assumptions, including risks
related to the clinical and formulation development of its product candidates,
the unproven nature of the Zalicus Ion channel drug discovery technology, and
those other risks that can be found in the "Risk Factors" section of Zalicus'
annual report on Form 10-K on file with the Securities and Exchange Commission
and the other reports that Zalicus periodically files with the Securities and
Exchange Commission. Actual results may differ materially from those Zalicus
contemplated by these forward-looking statements. These forward-looking
statements reflect management’s current views and Zalicus does not undertake
to update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this release
except as required by law.
(c) 2013 Zalicus Inc. All rights reserved.
Justin Renz, 617-301-7575
Gina Nugent, 617-460-3579
Press spacebar to pause and continue. Press esc to stop.